Exosome-Mediated mRNA Delivery For SARS-CoV-2 Vaccination
Tsai, S.-J.; Guo, C.; Atai, N. A.; Gould, S. J.
Show abstract
Expression-dependent, Spike-only vaccines have been developed, deployed, and shown to be effective in the fight against SARS-CoV-2. However, additional approaches to vaccine development may be needed to meet existing and future challenges posed by emerging Spike variant strains, as well as a likely need for different antigen-delivery systems that are safe and effective for regular, periodic re-administration. We report here the development of mRNA-loaded exosomes, demonstrate that they can mediate the functional expression of heterologous proteins in vitro and in vivo, and have fewer adverse effects than comparable doses of lipid nanoparticles. Furthermore, we applied this approach to the development of an exosome-based, multiplexed mRNA vaccine that drives expression of immunogenic SARS-CoV-2 Nucleocapsid and Spike proteins. This vaccine elicited long-lasting cellular and humoral responses to Nucleocapsid and to Spike, demonstrating that exosome-based mRNA formulations represent a previously unexplored platform in the fight against COVID-19 and other infectious diseases.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Multivalent Exosome based protein vaccine: a "mix and match" approach to epidemic viruses' challenges. 98%
- Self-multimerization of mRNA LNP-derived antigen improves antibody responses 97%
- Cell-free screening, production and animal testing of a STI-related chlamydial major outer membrane protein supported in nanolipoproteins. 96%
Similar papers in this journal
- A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta 95%
- Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity 94%
- Polymeric Pathogen-like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus 94%
Similar papers in this journal
- A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability 97%
- mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates 96%
- Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference 95%
Similar papers in this journal
- A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice 97%
- Corticosteroids and cellulose purification improve respectively the in vivo translation and vaccination efficacy of self-amplifying mRNAs 95%
- mRNA-LNP vaccines against Hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models 95%
Similar papers in this journal
- A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection. 95%
- TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination 95%
- Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.